BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology

BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology

Date
February 16, 2017

London, UK: BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology.

Read BTG's press release

Novo Holdings uses cookies to ensure that we give you the best experience on our website. Read more